Dr. med. et phil. nat. David Semela
chief of service
Gastroenterology/Hepatology · Dept. I
MSD MK1308A-004
Jul 3, 2021Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
Clinical Studies - Jul 3, 2021 - Dec 3, 2022
Automatically Closed
Project leader: Semela David
Members: Stillhard Roman, Bergamin Irina
ESSENCE Study
Aug 1, 2020
Clinical Studies - Aug 1, 2020 - Dec 31, 2029
Ongoing
Project leader: Bilz Stefan
Members: Semela David, Räss Andrea, Stillhard Roman
COSMIC 312
Sep 1, 2019A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy Randomisation 2:1:1:1 Cabo...
Clinical Studies - Sep 1, 2019 - Nov 28, 2020
Completed
Project leader: Semela David
Members: Stillhard Roman
MSD-MK-3475 KEYNOTE 937
May 1, 2019A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant herapy in Participants ith Hepatocellular Carcinoma and Complete Radiological Response after Surgical esection or Local...
Clinical Studies - May 1, 2019 - May 1, 2026
Ongoing
Project leader: Semela David
Members: Stillhard Roman
ICL670, Deferasirox
Aug 1, 2017A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis
Clinical Studies - Aug 1, 2017 - Jan 1, 2020
Completed
Project leader: Semela David
Members: Stillhard Roman
Allergan AURORA
Apr 1, 2017A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis
Clinical Studies - Apr 1, 2017 - Jan 1, 2025
Aborted
Project leader: Semela David
GFT505-315
Mar 1, 2017A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis
Clinical Studies - Mar 1, 2017 - Nov 1, 2020
Aborted
Members: Stillhard Roman, Semela David
HEMATITE
Dec 16, 2016Quality of Life measurement using wrist actigraph in HCV genotype 1 infected, Treatment naive patients suffering from fatique and receiving Viekirax/Exviera.
Clinical Studies - Dec 16, 2016 - Dec 16, 2018
Completed
Project leader: Semela David
Members: Stillhard Roman
IDN-6556-14 NASH und Emricasan
Sep 14, 2016A Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Clinical Studies - Sep 14, 2016 - Sep 14, 2021
Aborted
Project leader: Semela David
Members: Alfter Christine
SASL 38 Swiss Cohort Study on Autoimmun Hepatitis
Sep 14, 2016Research project in which biological material is sampled from humans and health-related personal data is collected for research.
Clinical Studies - Sep 14, 2016 - Sep 14, 2022
Automatically Closed
Project leader: Semela David
Members: Stillhard Roman
SASL 39 Swiss Cohort Study on Primary Biliary Cholangitis
Sep 14, 2016Research project in which biological material is sampled from humans and health-related personal data is collected for research.
Clinical Studies - Sep 14, 2016 - Sep 14, 2022
Automatically Closed
Project leader: Semela David
Members: Stillhard Roman
SASL 40 Swiss Cohort Study on Primar Sclerosing Cholangitis
Jun 1, 2016Research project in which biological material is sampled from humans and health-related personal data is collected for research.
Clinical Studies - Jun 1, 2016 - Sep 14, 2022
Automatically Closed
Project leader: Semela David
Members: Stillhard Roman
Intercept 747-303 NASH and OCA
Mar 7, 2016A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
Clinical Studies - Mar 7, 2016 - Mar 7, 2021
Automatically Closed
Project leader: Semela David
Members: Alfter Christine
Intercept 747-302 PBC und OCA
Mar 7, 2016“A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis”
Clinical Studies - Mar 7, 2016 - Mar 7, 2021
Automatically Closed
Project leader: Semela David
Members: Alfter Christine
SASl 36 The health burden of Primary Biliary Cirrhosis in Switzerland
Mar 7, 2016
Clinical Studies - Mar 7, 2016 - Sep 14, 2016
Completed
Project leader: Semela David
Members: Alfter Christine
Swiss Hepatitis B Cohort Study
Mar 7, 2016Swiss Hepatitis B Cohort Study
Fundamental Research - Mar 7, 2016 - Mar 7, 2016
Automatically Closed
Project leader: Semela David
Members: Alfter Christine, Zeuge Ulf
Evaluation der diagnostischen Genauigkeit und Sicherheit des Einsatzes bereits etablierter Ultraschall- und Magnetresonanz-Techniken (Elastographie, Multiparametrische Bildgebung) zur nicht-invasiven Diagnostik von Leber-/Milzerkrankungen im Vergleich zur simultanen perkutanen Leberbiopsie
Mar 7, 2016Evaluation CAP vs. Histologie Stephan Baumeler, Irina Bergamin Zusammenarbeit mit USZ Christoph Gubler und Michael Scharl
Clinical Studies - Mar 7, 2016 - Mar 7, 2020
Automatically Closed
Project leader: Semela David
Members: Alfter Christine
Abbvie M13-590 “A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection
Jan 2, 2016
Clinical Studies - Jan 2, 2016 - Mar 2, 2017
Completed
Project leader: Semela David
Members: Alfter Christine
Abbvie M13-594 A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Ribavirin in Adults with Chronic Hepatitis C Virus Genotype 3 Infection
Jan 2, 2016
Clinical Studies - Jan 2, 2016 - Mar 2, 2017
Completed
Project leader: Semela David
Members: Alfter Christine
Evaluation of Controlled Attenuated Parameter (CAP) for Assessment of Liver Steatosis in an Unselected Population: a Single Center Real Life Experience
Dec 16, 2015Background & Aims: Controlled attenuated parameter (CAP) is a new parameter to assess steatosis of the liver, which is obtained together with elastography. Our aim was to assess the performance of CAP in an unselected population with different liver...
Clinical Studies - Dec 16, 2015 - Dec 16, 2017
Completed
Project leader: Baumeler Stephan
Members: Semela David, Bergamin Irina, Jochum Wolfram, Neuweiler Jörg